Cohort1: Synovial sarcoma
|
Administration route |
infusion |
Dosage |
0.5~5E9 cells |
Donor type |
Allogeneic |
Pts |
4 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Adverse reactions |
3/9(CRS); 1/9(lung injury) |
References |
PMID:
35768164
|
|
Cohort2: Breast cancer
|
Administration route |
infusion |
Dosage |
0.5~5E9 cells |
Donor type |
Allogeneic |
Pts |
1 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
References |
PMID:
35768164
|
|
Cohort3: Malignant salivary tumor
|
Administration route |
infusion |
Dosage |
0.5~5E9 cells |
Donor type |
Allogeneic |
Pts |
1 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
References |
PMID:
35768164
|
|
Cohort4: Melanoma
|
Administration route |
infusion |
Dosage |
0.5~5E9 cells |
Donor type |
Allogeneic |
Pts |
1 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
References |
PMID:
35768164
|
|
Cohort5: Ovarian cancer
|
Administration route |
infusion |
Dosage |
0.5~5E9 cells |
Donor type |
Allogeneic |
Pts |
1 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
References |
PMID:
35768164
|
|
Cohort6: Myxoid liposarcoma
|
Administration route |
infusion |
Dosage |
0.5~5E9 cells |
Donor type |
Allogeneic |
Pts |
1 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
References |
PMID:
35768164
|
|